Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.

Схожие документы

• Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
  по: Minhas, R, и др.
  Опубликовано: (2009)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
  по: Neil, A, и др.
  Опубликовано: (2003)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
  по: Neil, H, и др.
  Опубликовано: (2003)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
  по: Neil, H, и др.
  Опубликовано: (2004)
• CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis
  по: M. Doortje Reijman, и др.
  Опубликовано: (2024-03-01)